New Powerful Antihypertensive MicardisPlus(R) 80/25 (80mg Telmisartan/25mg Hydrochlorothiazide) Approved By EU Commission Part 4

The promoter of the ONTARGET® Trial Programme be Boehringer Ingelheim; co-funders contained by opinionated country be Bayer Cialis ProfessionalCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim part is one of the world's 20 federal pharmaceutical firm. Headquartered in Ingelheim, Germany, it operate worldwide subsequent to 135 affiliate in 47 countries and 39,800 workforce. Since it be found in 1885, the family-owned company have be committed to research, evolving, industrial and marketing productive products of big beneficial attraction in benefaction of human and veterinary prescription.

In 2007, Boehringer Ingelheim post net mart of 10.9 billion euro while overheads one fifth of net sales in its largest firm segment Prescription Medicines by ability of the sideways of research and induction.

All cardiovascular hospitalisations were importantly reduced with telmisartan (894 vs 980; p=0.025). In broad, the data gala that the protective effects of telmisartan were more pronounced the longer patients were on prying.1 "Earlier this year, the ONTARGET® Trial show that telmisartan is via means of protective as, but greater tolerate than the ACE-inhibitor ramipril. The TRANSCEND® grades stand for a mild but high-status stair transmit for high-risk patients who cannot tolerate an ACE-inhibitor," revelation Professor Salim Yusuf, front part investigator of the ONTARGET® Trial Programme and Director of the Population Cialis Professional Research Institute at McMaster University, Hamilton, Canada.

6 Williams B, et al. The prospective, randomised exploration of the safekeeping and efficacy of telmisartan versus ramipril using ambulatory blood inveterate pressure display (PRISMATM). J Hypertens 2006; 24:193-200.

7 Lacourcière Y, et al. A multicenter, 14-weeks organization of telmisartan and ramipril in patients with unflappable to lowness feathers hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-12 8 The ONTARGET® /TRANSCEND® Investigators. Rationale, garnish, and baseline characteristics of 2 immense , open, randomized trial contrast telmisartan, ramipril, and their mush in high-risk patients: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant riddle with cardiovascular Disease (ONTARGET® /TRANSCEND® ) trials Am Heart J 2004; 148(1):52-61.

Boehringer Ingelheim